Onesource Specialty Pharma Ltd. (ONESOURCE) — key facts
NSE-listed · Healthcare. Data as of 11 Nov 2026 (IST) from InvestSights.
Last close: ₹1,613.5 (-1.17% day change)
Key ratios
- P/B ratio
- 2.89
- ROE (%)
- -1.27
- ROCE (%)
- 0.37
- Debt/Equity
- 0.26
- Dividend yield (%)
- 0
- Market cap (₹ Cr)
- 18,502.62
Forensic checks
Piotroski F-Score: 1/9 · Altman Z-Score: 5.83 · Beneish M-Score: -2
InvestSights quality score
48.2/100 — Below Average (descriptive data-driven composite; not a recommendation)
Latest earnings call (Q2 FY27)
AI summary: The central signal is that OneSource’s FY28 outlook increasingly depends on converting newly commissioned DDC capacity into commercial semaglutide volumes while preserving the operating leverage already visible in Q2 FY27. Management reiterated $400 million revenue and $160 million reported EBITDA for FY28 after quarterly revenue grew 37% year-on-year and EBITDA margin…
Full analysis on InvestSights
InvestSights is an analytics platform and is not SEBI-registered as a Research Analyst or Investment Adviser. All figures are educational, descriptive data — not investment advice. Consult a SEBI-registered adviser before investing.